CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil
AUTOR(ES)
MÜLLER, TALISE E., ELLWANGER, JOEL H., MICHITA, RAFAEL T., MATTE, MARIA CRISTINA C., RENNER, JANE D.P.
FONTE
An. Acad. Bras. Ciênc.
DATA DE PUBLICAÇÃO
04/05/2017
RESUMO
ABSTRACT This study aimed to identify the 516 G>T polymorphism of the CYP2B6 gene and evaluate its influence on central nervous system (CNS) side effect development in HIV-positive individuals undergoing Efavirenz (EFV) treatment in a population from southern Brazil. Additionally, we performed a survey on the clinical and epidemiological characteristics of our sample. In addition to medical records evaluation, whole blood of 89 individuals was analyzed for viral load, T lymphocyte count (CD4+ and CD8+), and the polymorphism. Considering the side effects of the CNS reported by individuals but without considering the genetic variables, no statistically significant association was noted between the adverse effects and the antiretroviral treatment (including or not EFV). In addition, no statistically significant difference was noted for the influence of genotype on the viral load or the number of T lymphocytes (CD4+ and CD8+) among individuals undergoing EFV treatment. This is the first study that investigated the impact of the 516 G>T polymorphism of the CYP2B6 gene among HIV-positive individuals from southern Brazil. Its clinical significance indicates the need for prospective studies in this population.
Documentos Relacionados
- Associated factors of efavirenz plasma levels in hiv-positive individuals with viral supression
- Oral lesions frequency in HIV-positive patients at a tertiary hospital, Southern Brazil
- Different nutritional-state indicators of HIV-positive individuals undergoing antiretroviral therapy
- Predictors of undetectable plasma viral load in HIV-positive adults receiving antiretroviral therapy in Southern Brazil
- beta-2 Microglobulin values among human immunodeficiency virus (HIV)-negative, HIV-positive asymptomatic, and HIV-positive symptomatic Ugandans.